United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
SAN DIEGO, Jan. 27, 2016 -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage, Chief Executive Officer, will present at the Leerink Partners 5th Annual Global Healthcare Conference in New York City on Wednesday, February 10, 2016 at 3:30 p.m. ET.
A live webcast of the presentation will be available at http://ir.retrophin.com/events.cfm and archived for replay through Tuesday, May 10, 2016.
About Retrophin
Retrophin is a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases for which there are currently no viable options for patients. The Company's approved products include Chenodal®, Cholbam®, and Thiola®, and its pipeline includes compounds for several catastrophic diseases, including focal segmental glomerulosclerosis (FSGS), pantothenate kinase-associated neurodegeneration (PKAN), nephrotic syndrome and others. For additional information, please visit www.retrophin.com.
Contact: Chris Cline, CFA Director, Investor Relations 646-564-3680 [email protected]
